Rare Bleeding Disorders Factor XI deficiency FX deficiency Fibrinogen deficiency Dr Niamh O’Connell The National Centre for Hereditary Coagulation Disorders,

Slides:



Advertisements
Similar presentations
Coagulopathy and blood component transfusion in trauma
Advertisements

Venous Thrombo-embolism In Pregnancy
Venous Thromboembolism: Risk Assessment and Prophylaxis
BLEEDING DISORDERS AN OVERVIEW WITH EMPHASIS ON EMERGENCIES.
Fetal Pillow Experience at SWBH NHS Trust Birmingham Mr.R.Ganapathy
Prophylaxis of Venous Thromboembolism
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Increasingly, women who are asymptomatic present in pregnancy with a known thrombophilia, typically detected because of screening following identification.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
Clinical Experience with octaplas®/octaplasLG®
Octaplex – The Modern PCC
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Anticoagulation In Dental Procedures Galila Zaher MRCPath KAU Assistant Professor.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
An Introduction to Haemophilia and related bleeding disorders M QARI, MD, FRCPA.
Hemophilia A By Marissa Miuccio.
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
Background Methods Results Conclusion Acknowledgements Printed by Multi-Institutional Audit of octaplex® & Comparison with National Recommendations S.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Obstetric Haemorrhage. Aims To recognise Obstetric Haemorrhage To recognise Obstetric Haemorrhage To practise the skills needed to respond to a woman.
Fluids and blood products in trauma
Child with hematological dysfunction Emad Al Khatib, RN,MSN,CNS.
Shiraz University of Medical Science, Shiraz, Iran
Thrombolytic drugs BY :DR. ISRAA OMAR.
Thrombophilia National Haemophilia Director
FVIII PRODUCT USAGE IN CLINICAL SETTINGS TSEAC October 31, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER, FDA.
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
Routine clotting studies - a bloody waste of resources? Joanne Bratchell Lead Nurse Pre-operative Assessment St George’s Hospital, Tooting Antonia Field-Smith.
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Factor VII Deficiency Diagnosis and Management
Evaluating the efficacy of the B-lynch suture and the Bakri balloon, or both, in the treatment of severe post-partum haemorrhage Dr Ashleigh Smith Junior.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
TEMPLATE DESIGN © Reduced Fetal Movements as a Predictor of Fetal Compromise Dr. Meenu Sharma Lancashire Teaching Hospital.
General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.
DIC. acute, subacute or chronic widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural.
Event and Peri-procedural Replacement Therapy in Patients with Hemophilia.
Guidelines on the investigation and management of the APL syndrome Dr Wan Zaidah Abdullah BJH : (Revised of !991 guidelines by the Haemostasis.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Anthony K. C. Chan Professor, Department of Pediatrics McMaster Children’s Hospital/Hamilton Health Sciences Foundation Chair in Pediatric Thrombosis and.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Management Control or elimination of the underlying cause Severe DIC: – Control of hemodynamic parameters – Respiratory support – Surgery Attempts to treat.
Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.
Approach To Bleeding Disorders In Neonates
Hemophilia 2009.
Immunological disorder during pregnancy
Coagulation cascade:.
AUB:Iatrogent Coagulopathy
Recent advances- Novoseven
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
Audit of Blood Product Use in Paediatric Cardiac Bypass Surgery.
Evaluation of Four Factor Prothrombin Complex Concentrate
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Introduction Discussion Case report References
Coagulation Screening In Elective & Emergency General Surgery
Tenecteplase (TNK-t-PA)‏
Thromboprophylaxis during labour and delivery
Using pharmacokinetics to individualize hemophilia therapy
C. Solomon, R.E. Collis, P.W. Collins  British Journal of Anaesthesia 
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Krop I et al. SABCS 2009;Abstract 5090.
Reversal of Direct Oral Anticoagulants (DOAC)
Individualizing Factor Replacement Therapy for Patients With Hemophilia.
Which NOAC and When for Stroke Prevention in AF?
Perioperative factor concentrate therapy
Periprocedural Management of Patients with Bleeding Disorders
Thrombophilia.
Thrombophilia in pregnancy: Whom to screen, when to treat
U. Alström, L.-Å. Levin, E. Ståhle, R. Svedjeholm, Ö. Friberg 
Dr. Festus Njuguna Moi University/MTRH
Presentation transcript:

Rare Bleeding Disorders Factor XI deficiency FX deficiency Fibrinogen deficiency Dr Niamh O’Connell The National Centre for Hereditary Coagulation Disorders, St. James’s Hospital, Dublin

doi: /bjh British Journal of Haematology, 2014, 167, 304–326

GRADE recommendations Strength of Recommendation Strong (grade 1): Certainty of effect Weak (grade 2): Benefits and risks finely balanced or uncertainty Quality of Evidence (A)High (B)Moderate (C)Low (D) Very Low

Factor XI deficiency Third commonest bleeding disorder in the UK Caused by variations in the F11 gene – higher prevalence in defined populations Bleeding associated with surgery, trauma, menorrhagia and PPH in women Severe bleeding more likely with FXI:C <0.1 iu/ml (EN-RBD registry Peyvandi J Thromb Haemost 2012) Bleeding variable in non-severe FXI deficiency

Which patient with Factor XI deficiency is at risk of bleeding...with surgery or delivery?

Recommendation 1 Cases with F11D should be identified as at a higher risk of bleeding if any of the following: the FXI activity is <0.1 iu/ml there is another coagulopathy there is a personal history of bleeding surgery is a dental extraction or involves the oropharyngeal or GU mucosa (2C)

Are Factor XI deficient patients likely to develop inhibitors?

Increased risk if very low levels FXI AND exposure to plasma or concentrate DOI:

Recommendation 2 Cases with FXI activity <0.1 iu/ml should be screened for FXI inhibitors before surgery or childbirth, if they have had previous FXI replacement therapy (2B).

What haemostatic treatment should be used for minor procedures?

Antifibrinolytics Increased bleeding rates in tissues with high fibrinolytic activity Tranexamic acid Used extensively No bleeding in 41 dental extractions in 19 severely deficient patients with a positive bleeding history Berliner et al, 1992

Recommendation 3 For minor bleeds or minor surgery in higher bleeding risk cases, and for all bleeds or surgery in low bleeding risk cases, consider tranexamic acid 15–20 mg/kg or 1 g four times daily for 5–7 d (2C).

In a patient with a higher bleeding risk, should concentrate or plasma be used for surgery or trauma related bleeding?

FXI concentrate and thrombosis Case reports prior to early/mid 1990s Changes in concentrate manufacture – Addition of anticoagulants Changes in clinical prescribing – Reduction in target FXI:C and dose – Caveat in patients with RF for thrombosis

242 Rx12 AEs8 Bleeding 4 Non- bleeding 1 thrombotic

FXI concentrate current approach Haemostatic FXI:C likely iu/ml – achieved by 10-15u/kg FXI concentrate or mls SD plasma Avoid FXI concentrate in patients with increased risk of thrombosis (if possible) No Tranexamic acid with FXI concentrate AEs are uncommon but bleeding is most likely AE!

Recommendation 4 For severe bleeds or major surgery in high bleeding risk cases, consider an initial dose of FXI concentrate 10–15 iu/kg, without additional tranexamic acid. A combination of SD-FFP 15–25 ml/kg and tranexamic acid 15–20 mg/kg or 1 g four times daily is an alternative to FXI concentrate (2C).

Does a FXI deficient woman need haemostatic cover for delivery?

27 studies, all observational 18% of 498 deliveries associated with PPH In 6 studies, prophylactic treatment was given to 21% of women No firm conclusion can be drawn from the available literature on optimum treatment or patient stratification

Recommendation 5 For delivery in all women with factor XI activity <0.15 iu/ml in the third trimester, consider FXI concentrate 10–15 iu/kg or SD- FFP 15–25 ml/kg and tranexamic acid 15–20 mg/kg at established labour or before caesarean section (2C).

Recommendation 6 For delivery in women with FXI activity 0.15– 0.7 iu/ml in the third trimester and a history of bleeding or no previous haemostatic challenges, consider tranexamic acid 15 mg/kg or 1 g four times a day continued for at least 3 d (2C).

Recommendation 7 For delivery in women with FXI activity 0.15– 0.7 iu/ml in the third trimester and no bleeding despite haemostatic challenges, only consider FXI concentrate or anti- fibrinolytics if abnormal bleeding occurs (2C).

What patients with FX deficiency need haemostatic treatment?

Bleeding phenotype in FX def Bleeding is more likely with FX <0.1 iu/ml and ICH, GI and joint bleeding if FX < 0.02 iu/ml Neonates may present with ICH and umbilical bleeding Surgery Obstetrics

Treatment options in FX def PCC iu/kg SD plasma mls/kg High purity FX concentrate Prospective, open-label, multicenter, non-randomized phase III study in 16 patients with severe/moderate factor X deficiency 98% of bleeds were controlled with 1 or 2 infusions 5 pts underwent 7 surgeries (4 major/3 minor) with excellent haemostasis No SAEs related to the product

Factor X deficiency

Fibrinogen deficiency Hypofibrinogenaemia Afibrinogenaemia Dysfibrinogenaemia – Haemorrhagic – Thrombotic

What patients with fibrinogen deficiency need treatment? Surgery – Levels and bleeding or thrombotic history. – Not all patients need Fibrinogen concentrate pre- operatively. “Watch and wait” Prophylaxis Afibrinogenaemia, Pregnancy Thromboprophylaxis

Fibrinogen deficiency

Thank You